Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp As Of April 15, 2024
- SEC Filing
- SEC Filing
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/28/2024 | $340.00 | Equal Weight | Wells Fargo | |
6/3/2024 | $315.00 | Hold | Jefferies | |
4/3/2024 | $400.00 → $365.00 | Buy → Neutral | Citigroup | |
12/7/2023 | $395.00 | Buy | UBS | |
6/16/2023 | $550.00 | Overweight | Wells Fargo | |
12/7/2022 | $565.00 | Outperform | RBC Capital Mkts | |
8/25/2022 | $715.00 | Outperform | Credit Suisse | |
5/24/2022 | Overweight → Equal-Weight | Stephens |
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (NASDAQ:OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, Oncocyte is poised for a transformative period with its upcoming commercial launches. The company's flagship products, the VitaGraft™ Kidney diagnostic test and its research use only (RUO) GraftAssure
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, at 2:15 PM Eastern Time (11:15 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life scien
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an illuminating interview with Oncocyte (NASDAQ:OCX) CFO Andrea S. James, who sheds light on her personal career path and the experiences that led to her senior role with the molecular diagnostics technology company. Oncocyte is a market disruptor with a mission to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. James states, "I built my career on the concept of disruptive technology, and I believe that what Oncocyte is offering is truly disruptive in i
8-K - Oncocyte Corp (0001642380) (Filer)
424B5 - Oncocyte Corp (0001642380) (Filer)
EFFECT - Oncocyte Corp (0001642380) (Filer)
The stock market is up solidly this year, thanks to expectations of rate cuts by the Federal Reserve amid easing inflationary pressure, strong corporate earnings and optimism over the potential of artificial intelligence technology’s potential. Building On Gains: The S&P 500 Index, a measure of broader market performance, has gained a robust 14.48% so far this year, and it is up 3.92% for the second quarter. The index last hit a record closing high (5,487.03) on June 18, and breached the 5,500 mark intraday on June 20. Since then, the broader gauge has been going about a consolidation move. The SPDR S&P 500 ETF Trust (NYSE:SPY), an exchange-traded fund that tracks the performance of th
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00
Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00
Citigroup downgraded Bio-Rad Labs from Buy to Neutral and set a new price target of $365.00 from $400.00 previously
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percent compared to $681.1 million reported for the second quarter of 2023. On a currency-neutral basis, quarterly sales decreased 5.4 percent compared to the same period in 2023. Life Science segment net sales for the second quarter were $250.5 million, a decrease of 16.5 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 15.9 percent compared to the same quart
IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may be accessed by visiting the "Events & Presentations" section of the Com
SC 13G - Oncocyte Corp (0001642380) (Subject)
SC 13D/A - Oncocyte Corp (0001642380) (Subject)
SC 13G/A - Oncocyte Corp (0001642380) (Subject)